Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 2
1991 1
1992 1
1994 2
1997 1
2002 2
2003 2
2004 6
2005 2
2012 5
2014 1
2017 1
2018 1
2019 1
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

18 results
Results by year
Filters applied: . Clear all
Page 1
Immunoassay Methods
Cox KL, et al. Assay Guidance Manual. Eli Lilly & Company and the National Center for Advancing Translational Sciences 2004– - Review. Among authors: Montrose C. PMID 22553884 Free Books and Documents.
HTS Assay Validation
Iversen PW, et al. Assay Guidance Manual. Eli Lilly & Company and the National Center for Advancing Translational Sciences 2004– - Review. Among authors: Montrose C. PMID 22553862 Free Books and Documents.
Data Standardization for Results Management
Campbell RM, et al. Assay Guidance Manual. Eli Lilly & Company and the National Center for Advancing Translational Sciences 2004– - Review. Among authors: Montrose C. PMID 22553865 Free Books and Documents.
Basics of Enzymatic Assays for HTS
Brooks HB, et al. Assay Guidance Manual. Eli Lilly & Company and the National Center for Advancing Translational Sciences 2004– - Review. Among authors: Montrose C. PMID 22553875 Free Books and Documents.
Receptor Binding Assays for HTS and Drug Discovery
Auld DS, et al. Assay Guidance Manual. Eli Lilly & Company and the National Center for Advancing Translational Sciences 2004– - Review. Among authors: Montrose C. PMID 22553864 Free Books and Documents.
Identification of a novel selective peroxisome proliferator-activated receptor alpha agonist, 2-methyl-2-(4-{3-[1-(4-methylbenzyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl]propyl}phenoxy)propanoic acid (LY518674), that produces marked changes in serum lipids and apolipoprotein A-1 expression
Singh JP, et al. Mol Pharmacol 2005. Among authors: Montrose C. PMID 15933217
Low high-density lipoprotein-cholesterol (HDL-c) is an important risk factor of coronary artery disease (CAD). Optimum therapy for raising HDL-c is still not available. ...The increase in HDL-c was associated with de novo synthesis of apoA-1....
Low high-density lipoprotein-cholesterol (HDL-c) is an important risk factor of coronary artery disease (CAD). Optimum therapy for ra …
18 results
Jump to page
Feedback